Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 30 Oct, 11:50 UTC

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

businessscience

Sources

• T2Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameBioPharma Dive / Healthcare Dive / MedTech Dive30 Oct, 11:50